Floatz logo

Atezolizumab

Metastatic Malignant Neoplasm in the Brain

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

102 Active assets in the Metastatic Malignant Neoplasm in the Brain cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Trastuzumab Deruxtecan
Baptist Health South Florida
Phase 4BB
Copper Cu 64-DOTA-Trastuzumab
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →